Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +50

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

📅 Biogen will present new Phase 2 AMETHYST Part A data for litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting, scheduled for March 27-31.

📊 The late-breaking results highlight the safety and efficacy of litifilimab, a first-in-class monoclonal antibody targeting BDCA2, in treating active subacute or chronic CLE.

✅ Litifilimab recently received FDA Breakthrough Therapy Designation for CLE, supported by positive outcomes from both the AMETHYST Phase 2 study and the earlier LILAC study.

🩺 CLE is a serious autoimmune disease lacking targeted treatments, often leading to permanent scarring, disfigurement, and significant impacts on patients' daily lives and mental health.

🔬 The AMETHYST trial is a two-part, double-blind, placebo-controlled study evaluating litifilimab versus placebo in patients refractory or intolerant to antimalarial therapy.

⏳ Phase 2 results are expected to be read out after the meeting, with the Phase 3 portion of the AMETHYST study on track for a data readout in 2027.

📍 The presentation titled "Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus" will occur on Saturday, March 28, at Bellco Theatre 3.

🧪 Biogen’s litifilimab targets blood dendritic cell antigen 2 (BDCA2) to reduce the production of pro-inflammatory molecules, including type-I interferon, in immune cells linked to lupus pathogenesis.

⚠️ Litifilimab remains an investigational therapeutic candidate that has not yet been approved by any regulatory authority, with its safety and effectiveness still being established.

💊 CLE currently has no approved targeted therapies since the last drug was approved in the 1950s, representing a significant unmet medical need for patients experiencing rashes, pain, and skin damage.

Bullish Signals
  • Biogen has received FDA Breakthrough Therapy Designation for litifilimab in cutaneous lupus erythematosus (CLE), with Phase 2 AMETHYST Part A results supporting this significant regulatory milestone.
  • Litifilimab is a first-in-class, monoclonal antibody targeting BDCA2, marking a novel mechanism of action with no other approved targeted therapies for CLE available since the 1950s.
  • Phase 3 part of the AMETHYST study is on track with a data readout expected in 2027, indicating sustained momentum and investment in the drug development program.
  • The company has demonstrated commitment to this area through decades of investment, highlighting the unmet medical need for patients facing permanent scarring and disfigurement from CLE.
  • Litifilimab (BIIB059) is being developed to treat patients with active subacute or chronic cutaneous lupus erythematosus who are refractory or intolerant to current antimalarial therapy options.
Risk Factors
  • Litifilimab remains an investigational therapeutic candidate that has not yet been approved by any regulatory authority, meaning its safety and effectiveness are not yet established.
  • The AMETHYST study is a long-duration, multicenter trial involving participants who are refractory or intolerant to antimalarial therapy, indicating the existing treatment landscape for Cutaneous Lupus Erythematosus remains limited and challenging.
  • Phase 3 part of the AMETHYST study has not yet been completed with a data readout expected in 2027, introducing significant time-to-market risk before potential commercialization.
  • Biogen disclosed that litifilimab is being investigated for systemic lupus erythematosus (SLE) as well as CLE, suggesting a broader development program with increased financial exposure and complexity.
  • The study design involves extended treatment periods up to 52 weeks with additional dosing schedules, which could lead to higher costs and potential safety signals not fully characterized at the Phase 2 stage.
Full Analysis
Biogen announced plans to present late-breaking Phase 2 AMETHYST data for litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting, scheduled for March 27-31. The presentation will feature results from AMETHYST Part A, a double-blind, placebo-controlled randomized Phase 2/3 study designed to evaluate the efficacy and safety of litifilimab compared to placebo in patients with active subacute or chronic CLE who are refractory or intolerant to antimalarial therapy. Litifilimab is described as a potential first-in-class monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), having recently received Breakthrough Therapy Designation from the FDA for CLE, a designation supported by both AMETHYST Part A results and previously presented Phase 2 LILAC study data. The disease-specific information highlights that CLE is a serious autoimmune condition impacting daily life, with potential to cause permanent scarring, disfigurement, and significant mental health burdens, while currently lacking approved targeted treatments since the last drug approval was in the 1950s. Biogen's litifilimab targets BDCA2 receptors on plasmacytoid dendritic cells (pDCs), inhibiting the production of pro-inflammatory molecules such as type-I interferon and other cytokines thought to play a major role in the pathogenesis of both systemic and cutaneous lupus. Diana Gallagher, MD, Senior Vice President at Biogen, stated that the data reflects decades of investment into CLE and that the Phase 3 portion of the AMETHYST study is on track with a data readout expected in 2027. The presentation schedule includes a specific talk titled "Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus (CLE): 24-week results of the Phase 2 Study, AMETHYST Part A" set for Saturday, March 28 at 5:24 PM ET. Additional on-site displays will focus on qualitative studies supporting content validity for disease assessment measures like CLA-IGA-R and correlations between CLASI and CLA-IGA-R in multi-center cross-sectional studies. Litifilimab is an investigational therapeutic candidate discovered and developed in-house by Biogen scientists, known as BIIB059, which has not yet been approved by any regulatory authority and whose safety and effectiveness have not been established for clinical use beyond the current trials. The AMETHYST study involves two parts, each with 52-week durations, where participants receive subcutaneous treatment every four weeks for 20 weeks followed by an additional dose at Week 2, with all participants receiving litifilimab during a 28-week extended treatment period from Weeks 24 to 48.